Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT07314229

Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor

Led by University Hospital, Lille · Updated on 2026-04-22

130

Participants Needed

1

Research Sites

67 weeks

Total Duration

On this page

Sponsors

U

University Hospital, Lille

Lead Sponsor

V

Vaincre la Mucoviscidose

Collaborating Sponsor

AI-Summary

What this Trial Is About

Cystic fibrosis is a genetic disorder affecting the entire body and associated with respiratory exacerbations, impaired quality of life and reduced life expectancy. The therapeutic management of cystic fibrosis has been profoundly changed by the recent arrival of a combination of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators, Elexacaftor-Tezacaftor-Ivacaftor (ETI), which improve quality of life, respiratory function and reducing the number of exacerbations. The impact of these treatments on exercise adaptation has not been clearly identified. The main objective is to estimate the prevalence of ventilatory reserve amputation during submaximal exercise testing assessed by the 6-minute walk test (6MWT) in patients with cystic fibrosis treated with ETIs.

CONDITIONS

Official Title

Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female
  • Adult aged 18 or over
  • Diagnosed with cystic fibrosis
  • Treated at the CRCM in Lille and Cr�e9teil
  • Currently treated with Elexacaftor-Tezacaftor-Ivacaftor (ETI)
  • Covered by social security
  • Able to understand study requirements, provide written informed consent, and comply with data collection
Not Eligible

You will not qualify if you...

  • Medical contraindication or inability to perform a stress test according to ERS recommendations
  • Exacerbation of cystic fibrosis in the 4 weeks before the first visit
  • Pregnant or breastfeeding women
  • Administrative reasons
  • Persons deprived of their liberty
  • Minors or legally protected adults
  • Persons who have refused or are unable to give informed consent
  • Persons in emergency situations

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University Hospital

Lille, France, 59037

Actively Recruiting

Loading map...

Research Team

C

Camille AUDOUSSET, Doctor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

HEALTH_SERVICES_RESEARCH

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here